Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide.
Future Oncol
; : 1-9, 2024 May 20.
Article
in En
| MEDLINE
| ID: mdl-38861305
ABSTRACT
Aim:
To describe overall survival, time to castration resistance and castration resistance-free survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide in a US oncology network. Patients &methods:
Patients with mCSPC initiating apalutamide on or after 17 September 2019 from an electronic health record-derived deidentified database were included. Patients were followed from apalutamide initiation and were censored at the earlier of end of clinical activity or data availability (31 October 2022).Results:
At 12 and 24 months, overall survival rates were 91.0 and 88.3%, rates of castration sensitivity were 85.7 and 72.1%, and castration resistance-free survival rates were 80.2 and 65.9%, respectively.Conclusion:
Real-world clinical outcomes of patients with mCSPC treated with apalutamide were comparable to results from the phase III TITAN trial.
This study looked at health outcomes among 176 patients receiving a prostate cancer medication, apalutamide. The average age of patients was 72 years, and approximately two-thirds of patients were White. Two years after starting apalutamide, most patients remained alive and their cancer did not progress.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Future Oncol
/
Future oncol
/
Future oncology
Year:
2024
Type:
Article
Affiliation country:
United States